ARS Pharmaceuticals, Inc. (SPRY)
5.89
-0.14
(-2.32%)
USD |
NASDAQ |
Aug 28, 16:00
5.89
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals Shareholders Equity (Quarterly) : 12.51M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.51M |
| March 31, 2026 | 61.31M |
| December 31, 2025 | 114.26M |
| September 30, 2025 | 147.66M |
| June 30, 2025 | 192.32M |
| March 31, 2025 | 228.97M |
| December 31, 2024 | 256.80M |
| September 30, 2024 | 200.98M |
| June 30, 2024 | 215.24M |
| March 31, 2024 | 223.87M |
| December 31, 2023 | 230.76M |
| September 30, 2023 | 237.28M |
| June 30, 2023 | 248.55M |
| March 31, 2023 | 261.16M |
| Date | Value |
|---|---|
| December 31, 2022 | 272.89M |
| September 30, 2022 | 267.07M |
| June 30, 2022 | 278.79M |
| March 31, 2022 | 293.23M |
| December 31, 2021 | 44.77M |
| September 30, 2021 | 332.13M |
| June 30, 2021 | 349.65M |
| March 31, 2021 | 368.55M |
| December 31, 2020 | 382.88M |
| September 30, 2020 | 138.32M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -5.603M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Passage Bio, Inc. | 4.456M |
| Vertex Pharmaceuticals, Inc. | 20.25B |
| Capricor Therapeutics, Inc. | 246.22M |
| Kyntra Bio, Inc. | -30.14M |
| Zentalis Pharmaceuticals, Inc. | 143.65M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 249.50M |
| Total Liabilities (Quarterly) | 236.98M |
| Debt to Equity Ratio | 7.727 |
| Current Ratio | 3.475 |
| Net Debt Paydown Yield | -2.43% |